# NCT07218913 (NCT07218913)

> Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07218913
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: Hearing Loss; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Nongerminomatous Germ Cell Tumor; Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor; Metastatic Testicular Seminoma; Stage II Testicular Cancer AJCC v8; Stage III Testicular Cancer AJCC v8
- Interventions: Audiometric Test; Cisplatin; Computed Tomography; Magnetic Resonance Imaging; Sodium Thiosulfate Anhydrous
- Enrollment: 44
- Primary outcome: Incidence of clinically meaningful ototoxicity

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07218913